A Retrospective Study on Clinical Characteristics and Outcomes of Patients With Pneumonia

ConditionPneumonia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZhonghao Fang

About this trial

Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging and the frequent emergence of drug-resistant bacteria; in China, severe pneumonia accounts for a striking 13.58% to 20.05% of hospitalized cases. In recent years, shifts in the pathogen spectrum (e.g., COVID-19, influenza A) and patient demographic characteristics have posed new challenges for clinical management. However, existing studies mostly focus on single pathogens or specific populations (e.g., ICU patients), lacking systematic analyses of the full-disease course characteristics of general hospitalized pneumonia patients. Furthermore, in the post-pandemic era, the clinical phenotypes, treatment responses, and prognostic factors of pneumonia may have evolved, necessitating evidence-based support from real-world data. This study aims to conduct a retrospective analysis to clarify the epidemiological characteristics, etiological distribution, and prognostic factors influencing current hospitalized pneumonia patients, thereby providing a basis for optimizing diagnosis and treatment strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years old;

Meet the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging);

Have a positive result from pathogen testing;

Time from onset to admission ≤ 72 hours (to ensure being in the acute phase of the disease);

Disqualifiers

1) Patients with severely lacking medical records;

Trial population

From April 2023 to April 2026, all adult patients who were hospitalized due to pneumonia and met the diagnostic criteria

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

500 Participants
are grouped into 1 trial group
Group A: pneumonia

Trial outcomes

Primary outcomes

1

28-day all-cause mortality rate

Time frame
28 days after admission

Secondary outcomes

1

Demographic characteristics

Demographic data (age, sex, etc.)

Time frame
28 days after admission
2

Comorbidities

Comorbidities, such as chronic obstructive pulmonary disease (COPD), diabetes mellitus, and cardiovascular diseases.

Time frame
28 days after admission
3

Symptomatic manifestations

Symptomatic manifestations (e.g., fever, cough, dyspnea)

Time frame
28 days after admission
4

Laboratory tests

Laboratory tests (including blood routine, liver and kidney function, etc.)

Time frame
28 days after admission

Other outcomes

1

Utilization of Antimicrobial Agents

Time frame
28 days after admission
2

Clinical Outcomes (cured, improved, deceased)

Time frame
28 days after admission

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Zhonghao Fang

Lead sponsor

Guangzhou Medical University

Sponsor institution

Fifth Affiliated Hospital of Guangzhou Medical University

Collaborator

This trial is not recruiting at the moment. You can still explore other options: